The company, a leader in phytochemical reference standards and contract research, announced a net loss attributable to common stockholders for the thirteen weeks ended October 2, 2010, of $883,223, compared with a net loss of $177,544 for the same period in 2009.
The net loss in Q3 2010 was attributable to an increase in share based compensation expenses of $423,764, compared with $55,947 for the Q3 2009, and the increased expenses related to pTerPure, said the company
“ChromaDex continues to work on implementing its business plan, which included the recent launch of pTeroPure pterostilibene as the next generation resveratrol,” said Frank Jaksch, CEO and co-founder of ChromaDex. “There are currently 12 products on the market containing pTeroPure pterostilbene and with this increased market adoption we are expecting many more over the next few months, which should give consumers many different options for supplementing with this very promising compound.”
As of October 2nd, 2010, cash, cash equivalents, and marketable securities totaled $2,985,632, added the company/